Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aligos Therapeutics, Inc. (ALGS : NSDQ)
 
 • Company Description   
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

Number of Employees: 93

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.10 Daily Weekly Monthly
20 Day Moving Average: 427,793 shares
Shares Outstanding: 42.69 (millions)
Market Capitalization: $46.97 (millions)
Beta: 3.52
52 Week High: $34.31
52 Week Low: $1.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.86% -10.86%
12 Week -54.92% -50.44%
Year To Date -90.73% -88.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE CORPORATE DR. 2ND FLOOR
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 800-466-6059
fax: -
cdavis@lifesciadvisors.com http://www.aligos.com
 
 • General Corporate Information   
Officers
Lawrence M. Blatt - Chief Executive Officer and Director
Leonid Beigelman - President and Director
Lesley Ann Calhoun - Executive Vice President; Chief Financial Officer
K. Peter Hirth - Director
Jack B. Nielsen - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 01626L105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 42.69
Most Recent Split Date: (:1)
Beta: 3.52
Market Capitalization: $46.97 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.31
Price/Cash Flow: -
Price / Sales: 7.80
EPS Growth
vs. Year Ago Period: -13.51%
vs. Previous Quarter: 5.62%
Sales Growth
vs. Year Ago Period: 182.53%
vs. Previous Quarter: 600.54%
ROE
03/31/22 - -75.34
12/31/21 - -67.03
09/30/21 - -62.43
ROA
03/31/22 - -59.20
12/31/21 - -54.33
09/30/21 - -51.31
Current Ratio
03/31/22 - 4.72
12/31/21 - 5.25
09/30/21 - 7.15
Quick Ratio
03/31/22 - 4.72
12/31/21 - 5.25
09/30/21 - 7.15
Operating Margin
03/31/22 - -2,263.64
12/31/21 - -2,944.02
09/30/21 - -
Net Margin
03/31/22 - -2,263.64
12/31/21 - -2,944.02
09/30/21 - -
Pre-Tax Margin
03/31/22 - -2,261.16
12/31/21 - -2,940.79
09/30/21 - -3,121.67
Book Value
03/31/22 - 3.58
12/31/21 - 4.33
09/30/21 - 5.09
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.15
12/31/21 - 0.14
09/30/21 - 0.02
 

Powered by Zacks Investment Research ©